Last reviewed · How we verify
NCT06987643: RESTORE
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
Phase 2 trial testing Neflamapimod in Moderate to Severe Acute Ischaemic Stroke in 90 participants. Currently enrolling.
31 May 2026
Quick facts
| Lead sponsor | EIP Pharma Inc |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 20 June 2025 |
| Primary completion | 31 May 2026 |
| Estimated completion | 28 June 2026 |
| Sites | 12 locations across Australia |
Drugs / interventions tested
- Neflamapimod — full drug profile →
- Placebo
Conditions studied
- Moderate to Severe Acute Ischaemic Stroke — all drugs for Moderate to Severe Acute Ischaemic Stroke →
- Ischaemic Stroke — all drugs for Ischaemic Stroke →
Sponsor
EIP Pharma Inc
Who can join
45 and older, any sex, with Moderate to Severe Acute Ischaemic Stroke or Ischaemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06987643
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neflamapimod
Trials testing the same drug.
- NCT05869669 — RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies · Phase 2 · completed
- NCT04001517 — Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies · Phase 2 · completed
Other EIP Pharma Inc trials
Trials by the same sponsor.
- NCT06815965 — A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies · Phase 2 · completed
- NCT05869669 — RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies · Phase 2 · completed
- NCT04001517 — Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies · Phase 2 · completed
- NCT03980938 — Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease · Phase 2 · terminated
- NCT03402659 — Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06987643 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EIP Pharma Inc
- Last refreshed: 9 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06987643.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing